Back to top
more

Denali Therapeutics (DNLI)

(Delayed Data from NSDQ)

$15.43 USD

15.43
1,122,303

+0.47 (3.14%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $15.42 -0.01 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Why Denali Therapeutics (DNLI) Stock Might be a Great Pick

Denali Therapeutics (DNLI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up

Denali (DNLI) reports lower than expected fourth-quarter financial results. The stock, however, rises 38% on news of funding raised by the company, which is expected to strengthen its cash position.

Denali's (DNLI) Pipeline Progresses Despite Stiff Competition

Denali (DNLI) forms strategic collaborations with bigwigs like Sanofi and Biogen to advance its pipeline. However, high dependence on partners for revenues remains a concern.

Fluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day

Fluor Corporation and Align Technology are part of the Zacks Bull and Bear of the Day article.

Sundeep Ganoria  headshot

3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024

Here we present three biotech stocks, SRPT, DNLI and VRNA, which took a beating in 2023 but have upside potential for 2024.

Does Denali Therapeutics Inc. (DNLI) Have the Potential to Rally 123.38% as Wall Street Analysts Expect?

The consensus price target hints at a 123.4% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Why Is Denali Therapeutics Inc. (DNLI) Down 5.2% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Wall Street Analysts See a 163.82% Upside in Denali Therapeutics Inc. (DNLI): Can the Stock Really Move This High?

The consensus price target hints at a 163.8% upside potential for Denali Therapeutics Inc. (DNLI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 13.25% and 88.33%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Denali Therapeutics Inc. (DNLI) Could Surge 121.53%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 121.5% in Denali Therapeutics Inc. (DNLI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.33% and 9.21%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Orchard Therapeutics PLC Sponsored ADR (ORTX) Surges 96.0%: Is This an Indication of Further Gains?

Orchard Therapeutics PLC Sponsored ADR (ORTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Denali Therapeutics Inc. (DNLI) Down 0.1% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Denali (DNLI) Q2 Earnings Beat on Higher Collaboration Revenues

Denali's (DNLI) second-quarter results are better than expected due to an increase in collaboration revenues under its agreement with Biogen.

Denali Therapeutics Inc. (DNLI) Tops Q2 Earnings and Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 251.16% and 2,502.86%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Denali (DNLI) Provides Update on Hunter Syndrome Study

Denali's (DNLI) early-to-mid-stage study of DNL310 shows a robust reduction in neurofilament light levels for patients with MPS II (Hunter syndrome).

Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Exelixis (EXEL) Down 0.6% Since Last Earnings Report?

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Denali Therapeutics Inc. (DNLI) Up 11.9% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novo Nordisk and Golden Entertainment have been highlighted as Zacks Bull and Bear of the Day

Novo Nordisk and Golden Entertainment are part of the Zacks Bull and Bear of the Day article.

Biogen (BIIB) to End One of Two Parkinson's Studies on BIIB122

Biogen (BIIB) is now set to focus on the LUMA study on its and partner Denali Therapeutics' (DNLI) small molecule LRRK2 inhibitor, BIIB122, for Parkinson's

Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?